ArticleClinical interventions in aging2026
Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson's Disease: A 3-Year Longitudinal Cohort Study.
Article in Clinical interventions in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subthalamic deep brain stimulation (STN-DBS) has emerged for Parkinson's disease (PD), but its long-term effects on levodopa-induced dyskinesia (LID) remain poorly understood. Objective: To assess the long-term LID outcomes and prognostic factors of STN-DBS. Methods: A single-blind longitudinal cohort study was conducted in evaluating 84 PD patients with LID (mean age 61.89 years; 46.4% female; mean disease duration 10.30 years; and mean baseline levodopa-equivalent dose 854.16 mg/day) who underwent STN-DBS at Beijing Tiantan Hospital, Capital Medical University between 2019 and 2021. Assessments at baseline, 1-year (short-term), and 3-year (long-term) regarding motor symptoms, quality of life, neuropsychological status, and cognitive function were analyzed. Primary outcomes focused on LID symptoms (Unified Dyskinesia Rating Scale [UDysRS]). Multivariable linear regression identified prognostic factors. Results: At 1-year, the UDysRS score improved significantly (74.4% reduction, Conclusion: STN-DBS was associated with significant long-term improvements in LID, although the effectiveness gradually declined. The identified prognostic factors help in patient selection and counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.